First Citizens Bank & Trust Co. Makes New $571,000 Investment in Hims & Hers Health, Inc. $HIMS

First Citizens Bank & Trust Co. acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,445 shares of the company's stock, valued at approximately $571,000.

Several other hedge funds also recently modified their holdings of HIMS. GAMMA Investing LLC increased its holdings in shares of Hims & Hers Health by 128.5% during the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company's stock worth $152,000 after buying an additional 2,892 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Hims & Hers Health by 42.8% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 12,588 shares of the company's stock worth $372,000 after buying an additional 3,770 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Hims & Hers Health during the first quarter worth approximately $257,000. Oppenheimer & Co. Inc. increased its holdings in shares of Hims & Hers Health by 8.5% during the first quarter. Oppenheimer & Co. Inc. now owns 39,289 shares of the company's stock worth $1,161,000 after buying an additional 3,079 shares in the last quarter. Finally, Perigon Wealth Management LLC increased its holdings in shares of Hims & Hers Health by 18.1% during the first quarter. Perigon Wealth Management LLC now owns 16,449 shares of the company's stock worth $486,000 after buying an additional 2,521 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

HIMS opened at $48.86 on Friday. The company has a fifty day moving average price of $51.14 and a two-hundred day moving average price of $49.66. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a 52 week low of $18.33 and a 52 week high of $72.98. The firm has a market capitalization of $11.04 billion, a PE ratio of 61.07, a P/E/G ratio of 3.38 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period in the prior year, the firm posted $0.06 EPS. Hims & Hers Health's revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In related news, insider Soleil Boughton sold 2,637 shares of the company's stock in a transaction on Monday, October 13th. The shares were sold at an average price of $54.38, for a total value of $143,400.06. Following the completion of the sale, the insider owned 161,130 shares in the company, valued at $8,762,249.40. This represents a 1.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of the company's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $506,060.50. Following the completion of the sale, the insider owned 169,940 shares of the company's stock, valued at approximately $8,581,970. This represents a 5.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,432,206 shares of company stock worth $74,248,448 in the last 90 days. Corporate insiders own 13.71% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on HIMS shares. KeyCorp started coverage on shares of Hims & Hers Health in a report on Tuesday. They set a "sector weight" rating for the company. Truist Financial lowered their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Canaccord Genuity Group reissued a "buy" rating and issued a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Reduce" and an average price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.